Analysis and Comparative Evaluation of Aortic Calcium by Computed Tomography and Histopathology in Patients With Aortic Stenosis
Analysis and Comparative Evaluation of Aortic Calcium by Computed Tomography and Histopathology in Patients With Aortic Stenosis
This study evaluates and compares aortic calcium by computed tomography and histopathology in
 patients with aortic stenosis.
1. Title

 Analysis and comparative evaluation of aortic calcium by computed tomography and
 histopathology in patients with aortic stenosis.

 2. Background.

 Calcified aortic valve disease (CAVD) was initially considered to be a passive
 degeneration of the extracellular matrix (EM). Recent studies have shown that within the
 development of the damage mechanism there is complexity and it is an active (1) and
 degenerative process where genetic, environmental and epigenetic phases overlap and
 interact leading to hemodynamic changes in blood flow, endothelial dysfunction and
 metabolic disorders that lead to low-density lipoprotein cholesterol deposits in the ME
 where at the same time there is an underlying infiltration of macrophages, oxidative
 stress, and release of pro-inflammatory cytokines. (2) However, although there are
 several theories of damage, and some of them are attributed to a diversity of origin
 such as genetic, congenital, infectious, and degenerative. Finally, the dynamic and
 functional impact of the heart affects equally. It leads to organic deterioration when
 the AD reaches clinical and echocardiographic criteria of severity, and the only
 therapeutic option is the change or replacement of the aortic valve.

 The participation of imaging methods such as computerized tomography about to the
 concerning the aortic valve through the measurement of the aortic calcium score (AVC-CT)
 as a method to determine the severity of aortic stenosis (AS) in those cases where
 echocardiographic measurements are conflicting, allows us to see the interest in
 defining this problem through different angles of investigation (7). In AD, progressive
 calcification is the trigger factor that also predominantly leads to aortic valve
 obstruction. (3) Currently, such calcification can be easily quantified using the same
 acquisition protocol and Agatston Scoring Method as used for a coronary artery calcium
 scan and is particularly attractive because it provides an assessment of the severity of
 AD, which is independent of the geometry and ventricular ejection fraction. Advances in
 the field of CT CVA measurement have been demonstrated in the last decade and are
 closely associated with hemodynamic measurements of moderate to severe AD in Doppler
 echocardiography, however, until recently, significant over-positioning of calcium from
 the aortic valve area among patients with hemodynamically severe AD and those with
 non-severe AD made it challenging to implement in clinical practice.

 This development has generated significant interest in the use of CT-CVA as an
 alternative and complementary assessment of the severity of AD, especially in patients
 with discordant echocardiographic findings. (11) In fact: 1) CVA is strongly but
 non-linearly associated with hemodynamic measures of severity in moderate to severe AD
 (12). Thus, the determination of CVA may help discriminate severe AD from non-severe AD
 in patients with discordant findings measured by echocardiography, and 3) in patients
 with moderate to severe AD, CVA is also likely associated with faster progression of AD
 and with survival. However, it should be mentioned that the analysis of that series did
 not make adjustments to the calcium measured in the patients' coronary artery. Although
 the CVA score has been recommended in the European Society of Cardiology Guidelines to
 confirm the severity of AD in the following conditions 1) patients with low left
 ventricular ejection fraction (LVEF), gradient and low flow, in which dobutamine stress
 echocardiography is inconclusive and 2) patients with low gradient AD and preserved
 LVEF, and this is not yet part of the American Heart Association (AHA) and American
 College of Cardiology (ACC) guidelines (13).

 So it has been suggested that clinical applicability should be established, so what are
 the next steps? While the reproducibility of coronary calcium quantification by
 multidetector CT has been tested for various workstation platforms before, (14,15) the
 same has not been done so far for CVA quantification through variability with standard
 Gold through the histopathological study and determine the variability of the CVA score
 measured by CT by determining its relationship through the flow and gradient status of
 patients with AD and define what implications can be suggested for the patient's
 treatment(13,16)

 3. Problem statement.

 There is a high prevalence of aortic valve calcification in patients who are subjected
 to valve change regardless of the cause (genetic, congenital, or degenerative structural
 malformation). Early identification of calcification in these patients is critical since
 they will receive a valve change that is likely to return to dysfunction if there is no
 history of the type of damage with or without preceding valve calcification. Currently,
 there is controversy about the ideal time to initiate valve therapy, as it has not been
 possible to identify those patients who will develop significant valve calcification.
 However, little is known about the relationship between the new imaging methods that are
 promising for measuring it and its correlation with standard gold, that is, what is
 quantified at the histopathological level.

 3.1. Justification.

 Magnitude: The global prevalence of aortic stenosis is 0.3-0.5% and 2-7% in >65 years
 and of valvular calcification. According to its definition and criteria to classify
 valve stenosis, up to 30% will require aortic valve change due to valve insufficiency.

 Significance: In the last two decades, the incidence of aortic valve insufficiency has
 increased exponentially and has been associated with unfavorable outcomes.

 Vulnerability: Currently, the cornerstone of aortic stenosis management includes
 prevention and early support management. The identification of calcification has not
 been entirely clear either through laboratory parameters or about to with concerning
 risk factors, which are inadequate and late. Early detection and intervention of
 calcification during the disease can improve the prognosis if it is recognized early.

 Feasibility: The study will be carried out in the two departments of Immunology through
 Dr. Soto who will coordinate the research) (Cardiovascular Medicine through Dr. Israel
 Pérez Torres who will evaluate calcification and histological changes in the valve
 tissue) (Pathology through Dr. Aranda who will manage and treat the valve samples) and
 the Image Department coordinated by Dr. Sergio Críales Vera who will quantify the valve
 calcium). All departments are recognized for their extensive participation in research.

 The study of the pathogenesis of persistent inflammatory damage in aortic stenosis in
 relation to the type of prosthesis will lead in the future to evaluate if it is a factor
 involved in the recurrent damage in stenosis, calcification, and deterioration. In the
 last decades in Mexico, the demographic transition increased the number of people over
 65 years old, the population in which the most significant complication of valve
 dysfunction has been seen. However, regardless of age and etiology, this is currently a
 population group with significant expansion and is expected to triple by 2030. This
 inflammatory damage will increase the prevalence of aortic stenosis, and therefore more
 patients will require valve replacement surgery.

 Our Institute is a national reference hospital that attends a significant number of
 patients with aortic stenosis, among others. Of the valves that are implanted, a quarter
 is manufactured at the Institute. Therefore, evaluating processes highly related to
 valve dysfunction such as calcification is a priority and is considered a health problem
 that requires prevention.

 3.2. Research question.

 In patients who have undergone aortic valve surgery, will the quantification of calcium
 using the 4D computerized tomography method have a reasonable correlation with that
 measured by histopathology, and will it also allow it to be proposed as an early
 predictor of dysfunction?

 4. Hypothesis.

 Working hypothesis (H1): The quantifiable assessment of valve calcium by CT is similar
 to that measured by histopathology and predicts early valve dysfunction.

 Null hypothesis (H0): The quantifiable assessment of calcium by CT scan is different
 from that measured by histopathology and does not predict early valve dysfunction.

 5. Methodology.

 5.1. Study design.

 Cohort, observational, comparative, and prospective study.

 5.2.5. Elimination criteria.

 a) Not having an adequate sample or staining of the valve tissue.

 5.3. Sample size.

 For the calculation of the sample size, a determination of the sample size (two tails)
 shall be made, taking into account the means and standard deviation (SD) of the items
 corresponding to each one. All patients who meet the inclusion criteria described above
 shall be considered for evaluation during the period 2017-2020.

 5.4. Data collection technique

 Data collection will be divided into three stages:

 Pre-surgical:

 Once the study population has been identified, a personal interview will be conducted,
 the objective of the study will be explained to the patient, and informed consent will
 be obtained. Various echocardiographic parameters will be collected for each patient
 (pre-surgical echocardiogram). The study of the valve, which is requested before
 surgery, will be analyzed in a tomography scan, and this is the one that will be used to
 measure the calcium.

 Post-surgery

 Employing the sample of the valve tissue obtained from the surgery, the appropriate cuts
 and stains for the measurement of the calcium will be requested.

 Echocardiographic study.

 The echocardiographic study performed will be re-evaluated by two expert
 echocardiographers following current recommendations.16 The Philips iE33 xMATRIX
 (Philips, Andover Massachusetts) ultrasound system with X5-1 transducer. The dimensions
 of the left ventricle will be quantified in the long parasternal axis; the volumes of
 the left atrium and left ventricle will be calculated with the Simpson method. The
 aortic valve area will be estimated with the continuity equation. The mass of the LV was
 estimated with the Devereaux method.17 The mean and maximum transvalvular aortic
 gradients will be acquired in the apical projection of three or five chambers, where a
 suitable continuous Doppler spectrum and the highest transaortic velocity were obtained.
 The pulmonary artery systolic pressure will be estimated by adding the right atrial
 pressure to the tricuspid insufficiency gradient.

 Computed tomography evaluation.

 The study was performed with a multidetector with double energy source of 256 cuts
 definition Flash Medical Systems Forcheim Germany (128 x 2), performing prospective
 additive in the best diastolic phase (65-70 %), with 3 mm thick reconstructions and 3mm
 spacing with Kernel B 35f filter and visual field adjusted only to the heart. The images
 were processed on a workstation (SmartScore by Syngo via, Waukeesha WI Electronics for
 Medicine. The results were expressed in Agatston units. The study was carried out
 without a contrast medium and with a radiation equivalent to 1.0 mSv.

 Tissue evaluation

 Histological technique.

 A 5-micron segment of the aortic valve, obtained by cardiothoracic surgery, was washed
 in 0.9% NaCl for 30 seconds immediately after the tissues were fixed by immersion in
 phosphate buffer with 10% formalin (pH 7.4) for 24 hours. Histological sections of the
 aortic valve were processed according to conventional histological procedures using Von
 Kossa staining. The technique is based on the reaction of silver nitrate in the presence
 of a reducing agent, usually, hydroquinone, resulting in insoluble silver phosphate that
 can be seen under the microscope in black. Histological sections were analyzed using a
 Carl Zeiss light microscope (Carl Zeiss, West Germany, Germany) (model 63,300) equipped
 with a Tucsen digital camera (9 megapixels) with TSview 7.1 software (Tucsen Imaging
 Technology Co., Ltd. Chuo, Japan, at 25x magnification. The photomicrographs were
 analyzed by densitometry using Sigma Scan Pro 5 Systat Software Inc. San Jose,
 California, CA, USA. Density values are expressed as pixel units.

 6. Statistical analysis plan.

 Categorical variables were expressed as proportions, continuous variables as means with
 standard deviation or median with interquartile range according to the distribution.
 Comparisons will be made for categorical variables with Chi-square or Fisher exact test and
 dimensional variables with Student t or Mann-Whitney U. Correlations with Pearson's r for
 quantitative variables or Spearman's rho for qualitative variables. Related samples were
 analyzed with ANOVA for repeated measurements and Friedman's test according to distribution
 with post-hoc analysis to identify differences between groups. The diagnostic test study will
 include the ROC curve to analyze cut-off points. The p-value of statistical significance was
 established to be less than 0.05 at two-tailed. Statistical analysis was performed with SPSS
 version 22 software (SPSS Inc. Chicago, Illinois).
Inclusion Criteria:

 1. Patients who are candidates for aortic valve replacement.

 2. Age greater than or equal to 18 years of age.

 3. Both genders.

 4. With any associated comorbidity

 5. Any etiology

 6. Hospitalized and with an echocardiographic study showing the variables to be studied

 7. Informed Consent.

 Exclusion Criteria:

 1. Patients who have previously undergone other aortic valve surgery

 2. Patients who have received contrast medium ≤24 hours.

 3. Patients on hemodialysis.

 4. Patients with infection.

 5. Patients with cancer.

 6. Patients with autoimmune diseases.

 7. Pregnant women.

 8. Patients who refuse to be included.